Joseph Kass
Neurology · Houston, TXNPI 1124135157
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,930 of the $11,051 with a category attached, or 89.9%. Eisai Inc. accounts for 97.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $4,451 and has fallen 97.5% since, to $113 in 2025.
Across 16 payments — averaging $690.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$11K
- Argenx US, Inc.$113
- Medtronic$90
- Biogen$53
- Novartis$25
Across 114 payments — averaging $32,689 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2M
- Eisai Inc.$600K
- Eli Lilly$519K
- Novartis$356K
- Genentech, Inc.$225K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
What the payments were for
- Consulting fees$9,93090%
- Travel & lodging$5695%
- Food & beverage$5525%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 11 | $10,770 |
| Argenx US, Inc. | 1 | $113 |
| Medtronic | 1 | $90 |
| Biogen | 2 | $53 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$113
How this compares
$11,051 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 13 | $176 |
Paid to pharmacies, not to this prescriber.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.